David Kobiler
Overview
Explore the profile of David Kobiler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glinert I, Bar-David E, Ben-Shmuel A, Sittner A, Puni R, Laredo S, et al.
PLoS One
. 2023 Feb;
18(2):e0281879.
PMID: 36795682
Bacillus anthracis overcomes host immune responses by producing capsule and secreting toxins. Production of these virulence factors in response to entering the host environment was shown to be regulated by...
2.
Sittner A, Ben-Shmuel A, Glinert I, Bar-David E, Schlomovitz J, Kobiler D, et al.
PLoS One
. 2020 Feb;
15(2):e0228917.
PMID: 32053632
As Bacillus anthracis spores pose a proven bio-terror risk, the treatment focus has shifted from exposed populations to anthrax patients and the need for effective antibiotic treatment protocols increases. The...
3.
Glinert I, Weiss S, Sittner A, Bar-David E, Ben-Shmuel A, Schlomovitz J, et al.
Toxins (Basel)
. 2018 Dec;
10(12).
PMID: 30513757
Nonencapsulated (∆pXO2) strains are commonly used as vaccines and for anthrax research, mainly in the mouse model. Previously, we demonstrated that the infection of rabbits, intranasally or subcutaneously, with the...
4.
Ben-Shmuel A, Glinert I, Sittner A, Bar-David E, Schlomovitz J, Brosh T, et al.
Antimicrob Agents Chemother
. 2018 Apr;
62(7).
PMID: 29661872
Treatment of anthrax is challenging, especially during the advanced stages of the disease. Recently, the Centers for Disease Control and Prevention (CDC) updated its recommendations for postexposure prophylaxis and treatment...
5.
Sittner A, Bar-David E, Glinert I, Ben-Shmuel A, Weiss S, Schlomovitz J, et al.
PLoS One
. 2017 Nov;
12(10):e0186613.
PMID: 29088287
Hemorrhagic meningitis is considered a complication of anthrax and was reported in about 50% of deadly cases in humans and non-human primates (NHP). Recently we demonstrated in Guinea pigs and...
6.
Glinert I, Bar-David E, Sittner A, Weiss S, Schlomovitz J, Ben-Shmuel A, et al.
Antimicrob Agents Chemother
. 2016 Jun;
60(8):4878-85.
PMID: 27270276
Protective antigen (PA)-based vaccines are effective in preventing the development of fatal anthrax disease both in humans and in relevant animal models. The Bacillus anthracis toxins lethal toxin (lethal factor...
7.
Weiss S, Altboum Z, Glinert I, Schlomovitz J, Sittner A, Bar-David E, et al.
Antimicrob Agents Chemother
. 2015 Sep;
59(12):7497-503.
PMID: 26392505
Respiratory anthrax is a fatal disease in the absence of early treatment with antibiotics. Rabbits are highly susceptible to infection with Bacillus anthracis spores by intranasal instillation, succumbing within 2...
8.
Levy H, Glinert I, Weiss S, Bar-David E, Sittner A, Schlomovitz J, et al.
PLoS One
. 2014 Nov;
9(11):e112319.
PMID: 25375158
Infection of the central nervous system is considered a complication of Anthrax and was reported in humans and non-human primates. Previously we have reported that Bacillus anthracis possesses a toxin-independent...
9.
Levy H, Glinert I, Weiss S, Sittner A, Schlomovitz J, Altboum Z, et al.
PLoS One
. 2014 Jan;
9(1):e84947.
PMID: 24416317
The accepted paradigm states that anthrax is both an invasive and toxinogenic disease and that the toxins play a major role in pathogenicity. In the guinea pig (GP) model we...
10.
Levy H, Weiss S, Altboum Z, Schlomovitz J, Glinert I, Sittner A, et al.
Infect Immun
. 2012 May;
80(8):2623-31.
PMID: 22585968
The virulence of Bacillus anthracis, the causative agent of anthrax, stems from its antiphagocytic capsule, encoded by pXO2, and the tripartite toxins encoded by pXO1. The accepted paradigm states that...